.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR22_EmtricitabineTenofovirAlafenamid.EmtricitabineTenofovirAlafenamid .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR22_EmtricitabineTenofovirAlafenamid.EmtricitabineTenofovirAlafenamid| name: | EmtricitabineTenofovirAlafenamideDarunavirAndCobicistat |
| ATC code: | J05AR22 | route: | oral |
| n-compartments | 2 |
Emtricitabine, tenofovir alafenamide, darunavir, and cobicistat is a fixed-dose combination antiretroviral medication used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents. The combination includes two nucleoside reverse transcriptase inhibitors (emtricitabine, tenofovir alafenamide), a protease inhibitor (darunavir), and a pharmacokinetic enhancer (cobicistat). The medicine is approved for use, commonly marketed in fixed-dose combinations, such as Symtuza.
Estimated pharmacokinetic parameters based on available published information for each constituent in healthy adult subjects after oral administration in the fixed-dose combination. Specific published pharmacokinetic models for the combination product are not available.